Hepatitis B vaccine and dialysis: Current issues

International Journal of Artificial Organs

Volumn 24, Issue 10, 2001, Pages 683-694

  Fabrizi, F ^a   Martin, P ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

'CURRENT; HEPATITIS B;

ALPHA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; LEVAMISOLE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT HEPATITIS B VACCINE; RECOMBINANT INTERLEUKIN 2; THYMOPENTIN; ZINC;

CHRONIC KIDNEY FAILURE; CHRONIC LIVER DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INFECTION RISK; LIVER CANCER; LIVER CELL CARCINOMA; NONHUMAN; PREVALENCE; PROPHYLAXIS; REVACCINATION; REVIEW; SEROCONVERSION; VACCINATION; VACCINE PRODUCTION; VIRUS CARRIER;

EID: 0035203325     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880102401003     Document Type: Review

References (98)

1. Global programme for control of hepatitis B infection
2. Hemodialysis-associated hepatitis in the United States, 1974
3. Chronic viral hepatitis and the management of chronic renal failure
4. National surveillance of dialysis-associated diseases in the United States, 1977
5. HBV and HCV infections in relation to the chosen genetic features in hemodialyzed patients
6. Serological and vaccination profile of hemodialysis patients during an outbreak of hepatitis B virus infection
7. Hepatitis C and hepatitis B virus infection in hemodialysis patients and staff: A two year follow-up
8. Hepatitis virus infection in haemodialysis patients from Moldavia
9. Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: Yellow spots on a black map?
10. Incidence and risk factors for hepatitis B virus and hepatitis C virus infection among haemodialysis and CAPD patients: Evidence for environmental transmission
11. The hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: Recommendations of the Immunization Practices Advisory Committee
12. Vaccines to prevent viral hepatitis
13. Molecular virology and pathogenesis of hepatitis B
14. Allelic subtypic determinants of hepatitis B surface antigen (i and t) that are distinct from d/y or w/r
15. Viral subtypes and cross-protection in hepatitis B virus infections in chimpanzees
16. Hepatitis B vaccine in medical staff of hemodialysis units: Efficacy and subtype protection
17. Loss of the common 'A' determinant of hepatitis B surface antigen by a vaccine-induced escape mutants
18. A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: Protective efficacy in chimpanzees
19. Antibodies to a synthetic peptide from the pre-S 120-145 region of the hepatitis B virus envelope are virus-neutralizing
20. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen
21. Immune response to the pre-S (1) region of the hepatitis B surface antigen (HBsAg): A pre-S(1)-specific T cell response can bypass non-responsiveness of the pre-S(2) and S regions of HBsAg
22. Vaccination against hepatitis B: The Italian strategy
23. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan
24. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
25. Hepatitis B virus infection: A comprehensive immunization strategy to eliminate transmission in the United States, 1999 update. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
26. Notice to readers: Recommended childhood immunization schedule-United States, 2000
27. Active and passive immunization
28. Suboptimal response to hepatitis B vaccine given by injection into the buttock
29. Vaccine recommendations for patients on chronic dialysis
30. Vaccination of the dialysis patient
31. Hepatitis B vaccine in patients receiving hemodialysis
32. Randomised placebo controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, haemodialysis patients
33. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial
34. Protective effect of hepatitis B vaccine in chronic hemodialysis patients
35. Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients
36. Active hepatitis B vaccination of dialysis patients and medical staff
37. Hepatitis B vaccine: Randomized trial of immunogenicity in hemodialysis patients
38. Vaccination against hepatitis B in renal dialysis units: Short or normal vaccination schedule?
39. Immune response to two different hepatitis B vaccines in haemodialysis patients: A two year follow-up
40. Immune response to hepatitis B vaccine in hemodialysis patients
41. Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Wisconsin
42. Long-term evaluation of the hepatitis B vaccine in hemodialysis patients
43. Vaccination against hepatitis B in children and adolescent patients on dialysis
44. Factors influencing the response to hepatitis B vaccination of hemodialysis patients
45. HLA heterogeneity of hepatitis B vaccine response in hemodialyzed patients
46. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients
47. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients
48. Immunogenicity of a recombinant DNA hepatitis B vaccine in patients with chronic renal failure
49. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients. A two year follow-up
50. Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients
51. Poor response to a recombinant hepatitis B vaccine in dialysis patients
52. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients
53. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients
54. Long-term immunogenicity and protective efficacy of recombinant DNA yeast-derived vaccine in hemodialysis patients
55. Antibody level after hepatitis B vaccination in hemodialysis patients: Influence of hepatitis C virus infection
56. Hepatitis B virus infection in chronic uremia: Long-term follow-up of a two-step integrated protocol of vaccination
57. Recombinant hepatitis B vaccine use in chronic hemodialysis patients: Long-term evaluation and cost-effectiveness analysis
58. Response to the hepatitis B virus vaccine in haemodalysis patients: Influence of malnutrition and its importance as a risk factor for morbidity and mortality
59. Hepatitis B vaccination in dialysis patients and nutritional status
60. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling
61. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients
62. Non-responsiveness to hepatitis B vaccination in haemodialysis patients: Association with impaired TCR/CD3 antigen receptor expression regulating costimulatory processes in antigen presentation and recognition
63. Production of interleukin-6, tumor necrosis factor and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients
64. More about response to hepatitis B vaccine in hemodialysis patients
65. Genetic prediction of nonresponse to hepatitis B vaccine
66. Genetic basis of nonresponse to hepatitis B vaccine in hemodialysis patients
67. Hepatitis B vaccination and booster in predialysis patients: A 4-year analysis
68. Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP)
69. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men
70. The effect of granulocyte-macrophage colony stimulating factor (M-CSF) on hepatitis B vaccination in haemodialysis patients
71. Granulocyte-macrophage colony stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients
72. Granulocyte-macrophage colony-stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients
73. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination
74. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients
75. Clinical experience with a new recombinant hepatitis B vaccine in previous non-responders with chronic insufficiency
76. Effect of oral levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients
77. Seroconversion rate, hepatitis B vaccination, and zinc supplementation
78. Zinc supplementation and hepatitis B vaccination in chronic haemodialysis patients: A multicentre study
79. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination
80. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine
81. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients
82. The effect of alpha interferon therapy and short-interval administration on response to hepatitis B vaccine in haemodialysis patients
83. Complete seroconversion by low-dose intradermal injection of recombinant hepatitis B vaccine in hemodialysis patients
84. Low repeated doses of intradermal hepatitis B vaccine produce protective levels of antibodies in hemodialysis patients, non-responding to usual and double multiple doses
85. Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients
86. Low dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure
87. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination
88. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients
89. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine
90. Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients
91. Intradermal versus intramuscular hepatitis B vaccination in non-responsive chronic dialysis patients: A prospective study with cost-effectiveness evaluation
92. Improvement of immune response in dialysis patients to Hevac B vaccine after multiple injections of vaccine
93. Appraisal of intradermal immunisation against hepatitis B
94. Vaccination against hepatitis B in patients with renal insufficiency
95. Hepatitis B vaccine in non-dialysed uraemic patients: Preliminary results